Department of Hematology/Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya, Japan.
Int J Hematol. 2013 Jan;97(1):147-50. doi: 10.1007/s12185-012-1246-z. Epub 2012 Dec 15.
Pulmonary hypertension (PH) is an infrequently reported complication after hematopoietic stem cell transplantation, and its etiology and therapeutic strategies, especially in infants, remain unclear. We report a case of severe PH that developed in an infant with acute leukemia following administration of busulfan as a preconditioner for cord blood transplantation; the case was successfully treated with sildenafil and beraprost, which to our knowledge is the first reported successful use of this regimen in PH following transplantation for infantile leukemia. From a review of all previous reports, use of busulfan in infants may raise the risk of developing PH, and unlike definitive pulmonary veno-occlusive disease, PH in this subgroup may be reversible by early detection and treatment.
肺动脉高压(PH)是造血干细胞移植后少见的并发症,其病因和治疗策略,尤其是在婴儿中,仍不清楚。我们报告了一例急性白血病婴儿在接受环磷酰胺预处理后发生严重 PH 的病例;该病例使用西地那非和贝前列素成功治疗,据我们所知,这是首例报道的该方案在婴儿白血病移植后 PH 中的成功应用。通过对所有既往报告的回顾,在婴儿中使用白消安可能会增加发生 PH 的风险,与明确的肺静脉闭塞性疾病不同,该亚组的 PH 可能通过早期检测和治疗得到逆转。